FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3091714959> ?p ?o ?g. }

• W3091714959 endingPage "PR02" @default.
• W3091714959 startingPage "PR02" @default.
• W3091714959 abstract "Abstract Advances in our understanding of tumor immune biology and development of cancer immunotherapies have led to improved outcomes for patients who suffer from aggressive cancers such as melanoma. Despite the clinical success of immune checkpoint blockade, a majority of patients still fail to respond, and the underlying mechanisms that drive resistance remain unclear. To understand why a subset of tumors fail to respond to immunotherapy, we established a novel murine model of melanoma that is fully resistant to immune checkpoint blockade. By in vivo passaging nonresponding B16 melanoma tumor cells, we selected for a resistant variant that fails to respond to the combination of CTLA-4, PD-1, and PD-L1 blockade. In comparing gene expression of parental versus resistant tumor cells and analyzing the corresponding immune infiltrate, we determined the adaptations associated with resistance to therapy. We found that evasion of immunotherapy was associated with a “hypermetabolic” phenotype, characterized by an upregulation of glycolytic, oxidoreductase, and mitochondrial oxidative phosphorylation pathways to establish a hypoxic, metabolically hostile microenvironment. Enforced expression of two key genes associated with these pathways in parental tumor cells was sufficient to mediate resistance to triple checkpoint blockade. Flow cytometry assays determined that T cells infiltrating resistant tumors had diminished glycolytic capacity and effector function, indicating a metabolic disadvantage. Consistent with our findings, melanoma patients who failed dual checkpoint blockade exhibited similar metabolic alterations as seen in our resistant variant. Using a novel MRI-based imaging approach, we observed distinct metabolic changes that stratified responding versus nonresponding tumors in live mice. Applying this method to patients could provide insight into predicting response rates to checkpoint modulation. Overall, our data indicate that resistant melanoma tumor cells acquire a “hypermetabolic” phenotype to establish a hostile microenvironment that is capable of inhibiting the antitumor immune response. This abstract is also being presented as Poster A24. Citation Format: Ashvin R. Jaiswal, Arthur J. Liu, Shivanand Pudakalakatti, Prasanta Dutta, Priyamvada Jayaprakash, Todd Bartkowiak, Casey Ager, Zhiqiang Wang, Alex Reuben, Zachary Cooper, Cristina Ivan, Zhenlin Ju, Felix Nwajei, Jing Wang, Michael A. Davies, R. Eric Davis, Jennifer A. Wargo, Pratip K. Bhattacharya, David S. Hong, Michael A. Curran. Melanoma evolves complete immunotherapy resistance through acquisition of a hypermetabolic phenotype [abstract]. In: Proceedings of the AACR Special Conference on Melanoma: From Biology to Target; 2019 Jan 15-18; Houston, TX. Philadelphia (PA): AACR; Cancer Res 2020;80(19 Suppl):Abstract nr PR02." @default.
• W3091714959 created "2020-10-08" @default.
• W3091714959 creator A5008753971 @default.
• W3091714959 creator A5010299185 @default.
• W3091714959 creator A5014344399 @default.
• W3091714959 creator A5023083194 @default.
• W3091714959 creator A5026095888 @default.
• W3091714959 creator A5034240658 @default.
• W3091714959 creator A5034936114 @default.
• W3091714959 creator A5035427219 @default.
• W3091714959 creator A5037677450 @default.
• W3091714959 creator A5048327749 @default.
• W3091714959 creator A5054358636 @default.
• W3091714959 creator A5062622724 @default.
• W3091714959 creator A5065861312 @default.
• W3091714959 creator A5066060808 @default.
• W3091714959 creator A5066449720 @default.
• W3091714959 creator A5066807401 @default.
• W3091714959 creator A5071770314 @default.
• W3091714959 creator A5074743743 @default.
• W3091714959 creator A5082498438 @default.
• W3091714959 creator A5089753814 @default.
• W3091714959 date "2020-10-01" @default.
• W3091714959 modified "2023-09-22" @default.
• W3091714959 title "Abstract PR02: Melanoma evolves complete immunotherapy resistance through acquisition of a hypermetabolic phenotype" @default.
• W3091714959 doi "https://doi.org/10.1158/1538-7445.mel2019-pr02" @default.
• W3091714959 hasPublicationYear "2020" @default.
• W3091714959 type Work @default.
• W3091714959 sameAs 3091714959 @default.
• W3091714959 citedByCount "0" @default.
• W3091714959 crossrefType "journal-article" @default.
• W3091714959 hasAuthorship W3091714959A5008753971 @default.
• W3091714959 hasAuthorship W3091714959A5010299185 @default.
• W3091714959 hasAuthorship W3091714959A5014344399 @default.
• W3091714959 hasAuthorship W3091714959A5023083194 @default.
• W3091714959 hasAuthorship W3091714959A5026095888 @default.
• W3091714959 hasAuthorship W3091714959A5034240658 @default.
• W3091714959 hasAuthorship W3091714959A5034936114 @default.
• W3091714959 hasAuthorship W3091714959A5035427219 @default.
• W3091714959 hasAuthorship W3091714959A5037677450 @default.
• W3091714959 hasAuthorship W3091714959A5048327749 @default.
• W3091714959 hasAuthorship W3091714959A5054358636 @default.
• W3091714959 hasAuthorship W3091714959A5062622724 @default.
• W3091714959 hasAuthorship W3091714959A5065861312 @default.
• W3091714959 hasAuthorship W3091714959A5066060808 @default.
• W3091714959 hasAuthorship W3091714959A5066449720 @default.
• W3091714959 hasAuthorship W3091714959A5066807401 @default.
• W3091714959 hasAuthorship W3091714959A5071770314 @default.
• W3091714959 hasAuthorship W3091714959A5074743743 @default.
• W3091714959 hasAuthorship W3091714959A5082498438 @default.
• W3091714959 hasAuthorship W3091714959A5089753814 @default.
• W3091714959 hasConcept C121608353 @default.
• W3091714959 hasConcept C126322002 @default.
• W3091714959 hasConcept C170493617 @default.
• W3091714959 hasConcept C203014093 @default.
• W3091714959 hasConcept C2776107976 @default.
• W3091714959 hasConcept C2777658100 @default.
• W3091714959 hasConcept C2777701055 @default.
• W3091714959 hasConcept C2778468042 @default.
• W3091714959 hasConcept C2780674031 @default.
• W3091714959 hasConcept C2780851360 @default.
• W3091714959 hasConcept C502942594 @default.
• W3091714959 hasConcept C71924100 @default.
• W3091714959 hasConcept C86803240 @default.
• W3091714959 hasConcept C8891405 @default.
• W3091714959 hasConceptScore W3091714959C121608353 @default.
• W3091714959 hasConceptScore W3091714959C126322002 @default.
• W3091714959 hasConceptScore W3091714959C170493617 @default.
• W3091714959 hasConceptScore W3091714959C203014093 @default.
• W3091714959 hasConceptScore W3091714959C2776107976 @default.
• W3091714959 hasConceptScore W3091714959C2777658100 @default.
• W3091714959 hasConceptScore W3091714959C2777701055 @default.
• W3091714959 hasConceptScore W3091714959C2778468042 @default.
• W3091714959 hasConceptScore W3091714959C2780674031 @default.
• W3091714959 hasConceptScore W3091714959C2780851360 @default.
• W3091714959 hasConceptScore W3091714959C502942594 @default.
• W3091714959 hasConceptScore W3091714959C71924100 @default.
• W3091714959 hasConceptScore W3091714959C86803240 @default.
• W3091714959 hasConceptScore W3091714959C8891405 @default.
• W3091714959 hasIssue "19_Supplement" @default.
• W3091714959 hasLocation W30917149591 @default.
• W3091714959 hasOpenAccess W3091714959 @default.
• W3091714959 hasPrimaryLocation W30917149591 @default.
• W3091714959 hasRelatedWork W2049209548 @default.
• W3091714959 hasRelatedWork W2791825614 @default.
• W3091714959 hasRelatedWork W2803061034 @default.
• W3091714959 hasRelatedWork W3134152892 @default.
• W3091714959 hasRelatedWork W3153709335 @default.
• W3091714959 hasRelatedWork W3177607563 @default.
• W3091714959 hasRelatedWork W3217412908 @default.
• W3091714959 hasRelatedWork W4281389645 @default.
• W3091714959 hasRelatedWork W4285731353 @default.
• W3091714959 hasRelatedWork W4304979265 @default.
• W3091714959 hasVolume "80" @default.
• W3091714959 isParatext "false" @default.
• W3091714959 isRetracted "false" @default.
• W3091714959 magId "3091714959" @default.
• W3091714959 workType "article" @default.